Reuters logo
BRIEF-Janssen Pharmaceutica says Phase 3 Amber study achieved its primary endpoint​
2017年10月25日 / 中午12点11分 / 24 天前

BRIEF-Janssen Pharmaceutica says Phase 3 Amber study achieved its primary endpoint​

Oct 25 (Reuters) - Johnson & Johnson

* Investigational Darunavir-based single-tablet regimen shows positive results in previously untreated HIV patients in pivotal phase 3 Amber clinical trial

* Janssen Pharmaceutica NV - Phase 3 Amber study achieved its primary endpoint​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below